RC 552

Drug Profile

RC 552

Alternative Names: RC 552C

Latest Information Update: 15 Aug 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Corixa Corporation
  • Class
  • Mechanism of Action Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Reperfusion injury

Most Recent Events

  • 11 Nov 2003 No development reported - Phase-II for Ischaemic heart disorders in USA (Parenteral)
  • 11 Nov 2003 No development reported - Phase-II for Reperfusion injury in USA (Parenteral)
  • 14 Nov 2001 Phase-II clinical trials for Ischaemic heart disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top